Notable Labs (NASDAQ:NTBL) Receives “Market Outperform” Rating from JMP Securities

JMP Securities reissued their market outperform rating on shares of Notable Labs (NASDAQ:NTBL) in a research note released on Monday morning, Benzinga reports. The firm currently has a $9.00 target price on the stock.

Separately, Chardan Capital cut their price target on shares of Notable Labs from $9.00 to $7.00 and set a buy rating on the stock in a report on Monday.

Notable Labs Stock Up 1.7 %

NASDAQ:NTBL opened at $1.18 on Monday. The firm’s 50 day moving average price is $1.45. Notable Labs has a 52 week low of $1.01 and a 52 week high of $11.20. The company has a current ratio of 5.65, a quick ratio of 5.65 and a debt-to-equity ratio of 0.02. The stock has a market capitalization of $2.62 million, a PE ratio of -0.33 and a beta of 0.77.

Institutional Investors Weigh In On Notable Labs

An institutional investor recently bought a new position in Notable Labs stock. Industry Ventures L.L.C. bought a new position in Notable Labs, Ltd. (NASDAQ:NTBL) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 204,424 shares of the company’s stock, valued at approximately $386,000. Notable Labs comprises approximately 0.6% of Industry Ventures L.L.C.’s investment portfolio, making the stock its 6th biggest position. Industry Ventures L.L.C. owned 9.21% of Notable Labs at the end of the most recent quarter. Institutional investors and hedge funds own 70.48% of the company’s stock.

Notable Labs Company Profile

Notable Labs, Ltd., a clinical-stage platform therapeutics company, engages in developing predictive precision medicines for patients with cancer. The company, through its proprietary Predictive Precision Medicines Platform (PPMP), bio-simulates a cancer treatment and predicts, whether or not the patient is likely to respond to that specific therapeutic.